Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Chunli Medical (01858.HK) by 112,500 shares on November 21, 2025, marking a decrease of 0.25% [1][2] - Over the past five trading days, southbound funds have reduced their holdings on three occasions, with a total net reduction of 387,300 shares [1][2] - In the last 20 trading days, there have been 12 days of net increases in holdings by southbound funds, totaling 1,574,500 shares [1][2] Group 2 - As of now, southbound funds hold 44,596,100 shares of Chunli Medical, which represents 46.86% of the company's total issued ordinary shares [1][2] - Chunli Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with main products including joint prostheses and spinal implants [2] - The company's joint prosthesis products cover major human joints such as hip, knee, shoulder, and elbow, while its spinal implant products include a full range of spinal fixation systems [2]

Core Viewpoint - Spring Medical experienced a decline of 5.18% on November 21, with a trading volume of 61.44 million yuan and a market capitalization of 9.275 billion yuan [1] Company Overview - Spring Medical is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3] - The company is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its public listing on December 30, 2021 [7][8] Product and Market Position - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, along with a full range of spinal internal fixation systems [2][8] - The company has obtained registration certificates for surgical robots for hip and knee joint surgeries, as well as medical image processing software for surgical planning, indicating its investment in smart medical technology [2][3] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [9] Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Spring Medical was 6,164, an increase of 4.12% from the previous period, while the average circulating shares per person decreased by 3.95% [8] - The stock has seen a net outflow of 4.90 million yuan from major funds today, with a continuous reduction in major fund holdings over the past three days [4][5]

证券之星消息，截至2025年11月21日收盘，春立医疗(688236)报收于24.18元，下跌5.18%，换手率 0.86%，成交量2.49万手，成交额6144.13万元。 | 指标 | 春立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 92.75亿元 | 109.06亿元 | 38 124 | | 净资产 | 29.86亿元 | 38.93亿元 | 51 124 | | 净利润 | 1.92亿元 | 2.12亿元 | 33 124 | | 市盈率(动) | 36.32 | 54.54 | 42 124 | | 市净率 | 3.11 | 3.77 | 76 124 | | 毛利率 | 67.27% | 51.22% | 27 124 | | 净利率 | 25.34% | 9.57% | 22 124 | | ROE | 6.6% | 0.15% | 33 124 | 11月21日的资金流向数据方面，主力资金净流出848.37万元，占总成交额13.81%，游资资金净流出 188.7万元，占总成交额3.07%，散户资金净流入1037.07万元，占 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Spring Medical, including stock price movement and financing activities [1] - On November 20, Spring Medical's stock fell by 1.01%, with a trading volume of 27.14 million yuan, and a net financing outflow of 393,400 yuan [1] - As of November 20, the total margin balance for Spring Medical was 51.40 million yuan, accounting for 0.70% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with a primary focus on joint prosthetics and spinal implants [2] - The company reported a revenue of 756 million yuan for the first nine months of 2025, representing a year-on-year growth of 48.75%, and a net profit of 192 million yuan, which is a 213.21% increase compared to the previous year [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the last three years [3] Group 3 - As of September 30, 2025, the number of shareholders for Spring Medical increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 2.96 million shares, while two new shareholders, China Europe Economic Growth Mixed A and Ping An Low Carbon Economy Mixed A, are also noted [3]

Group 1 - The core viewpoint of the news is that Spring Medical has experienced a significant decline in stock price, dropping 5.1% on November 21, with a total market value of 9.282 billion yuan and a cumulative decline of 8.93% over six consecutive days [1] - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [1] - The company's revenue composition is heavily reliant on medical device products, accounting for 99.89% of total revenue, while other sources contribute only 0.11% [1] Group 2 - Among the top circulating shareholders of Spring Medical, a fund under China Europe Fund, specifically the China Europe Prosperity Selected Mixed A (020876), has recently entered the top ten, holding 2.8326 million shares, which is 0.74% of the circulating shares [2] - The fund has incurred a floating loss of approximately 3.6824 million yuan today and a total floating loss of 7.0815 million yuan during the six-day decline [2] - The China Europe Prosperity Selected Mixed A fund has shown a year-to-date return of 40.41% and a one-year return of 46.46%, ranking 1394 out of 8136 and 748 out of 8056 respectively [2]

Group 1 - Spring Medical announced a dividend of HKD 0.2304 per share, with an ex-dividend date of November 24, 2025, and a payment date of January 19, 2026. It is classified under the medical devices and supplies sector and is not part of the CSI Central Enterprises Dividend Index or the Hang Seng High Dividend Yield Index [1] - NetEase-S declared a dividend of USD 0.114 per share, with an ex-dividend date of December 4, 2025, and a payment date of December 16, 2025. It falls under the gaming software sector and is excluded from both the CSI Central Enterprises Dividend Index and the Hang Seng High Dividend Yield Index [1] - Kingsoft Technology Industrial announced a dividend of HKD 0.018 per share, with an ex-dividend date of December 24, 2025, and a payment date of January 8, 2026. It is categorized under consumer electronics and is not included in the CSI Central Enterprises Dividend Index or the Hang Seng High Dividend Yield Index [1] - Sa Sa International declared a dividend of HKD 0.0115 per share, with an ex-dividend date of December 3, 2025, and a payment date of December 19, 2025. It is classified in the skincare and cosmetics sector and is not part of the CSI Central Enterprises Dividend Index or the Hang Seng High Dividend Yield Index [1] Group 2 - The CSI Central Enterprises Dividend Index (931233.CSI) selects 50 listed companies with stable dividend levels and high dividend yields from the Hong Kong Stock Connect. As of November 20, the index has a one-year dividend yield of 5.63%, surpassing the 10-year government bond yield of 3.81%. The largest investment vehicle tracking this index is the Hong Kong Central Enterprises Dividend ETF (513910) [3] - The Hang Seng Mainland Enterprises High Dividend Yield Index (HSMCHYI.HI) includes high dividend stocks listed in Hong Kong from mainland companies. As of November 20, this index has a one-year dividend yield of 5.30%, which is higher than the 10-year government bond yield of 3.48%. The only ETF tracking this index is the Hang Seng Dividend ETF (159726) [3]

Group 1 - Spring Medical announced a dividend of HKD 0.2304 per share, with an ex-dividend date of November 24, 2025, and a payment date of January 19, 2026. It is classified under the medical devices and supplies sector and is not part of the Central Enterprises Dividend Index or the High Dividend Yield Index for Mainland Chinese Enterprises [1] - NetEase-S declared a dividend of USD 0.114 per share, with an ex-dividend date of December 4, 2025, and a payment date of December 16, 2025. It falls under the gaming software sector and is also excluded from the aforementioned indices [1] - Kingsoft Technology Industrial announced a dividend of HKD 0.018 per share, with an ex-dividend date of December 24, 2025, and a payment date of January 8, 2026. It is categorized under consumer electronics and is not included in the Central Enterprises Dividend Index or the High Dividend Yield Index [1] - Sa Sa International declared a dividend of HKD 0.0115 per share, with an ex-dividend date of December 3, 2025, and a payment date of December 19, 2025. It is classified in the skincare and cosmetics sector and is excluded from both indices [1] Group 2 - The Central Enterprises Dividend Index (931233.CSI) selects 50 listed companies with stable dividend levels and high dividend yields from the Hong Kong Stock Connect. As of November 20, the index has a one-year dividend yield of 5.63%, surpassing the 10-year government bond yield of 3.81%. The largest investment vehicle tracking this index is the Hong Kong Central Enterprises Dividend ETF (513910) [3] - The Hang Seng Mainland Enterprises High Dividend Yield Index (HSMCHYI.HI) includes high dividend stocks listed in Hong Kong from Mainland companies. As of November 20, this index has a one-year dividend yield of 5.30%, which is higher than the 10-year government bond yield of 3.48%. The only ETF tracking this index is the Hang Seng Dividend ETF (159726) [3]

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

11月19日，春立医疗跌0.73%，成交额3414.26万元。两融数据显示，当日春立医疗获融资买入额403.64 万元，融资偿还707.33万元，融资净买入-303.69万元。截至11月19日，春立医疗融资融券余额合计 5179.45万元。 融资方面，春立医疗当日融资买入403.64万元。当前融资余额5179.45万元，占流通市值的0.70%，融资 余额超过近一年90%分位水平，处于高位。 融券方面，春立医疗11月19日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年80%分位水平，处于高位。 来源：新浪证券-红岸工作室 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组 ...

| | 股東類型 | 稅率 | 有關代預扣所得稅之更多補充 | | --- | --- | --- | --- | | | | | （如適用） | | 非居民企業 | | | | | （非中國內地登記地址） | | 10% | 本公司向H股的非居民企業股東派 | | | | | 發股息時須按10%稅率代扣代繳企 | | | | | 業所得稅。 | | 非個人居民 | | | | | （非中國內地登記地址） | | 10% | 本公司向H股的個人股東(香港或澳 | | | | | 門居民或其他與中國簽訂稅收協議 | | | | | 的國家的居民)派發股息時須按 | | | | | 10%稅率代扣代繳個人所得稅。 | | 內地個人投資者或內地證券投 | | 20% | 本公司向此類股東派發股息時須按 | | 資基金通過滬港通或深港通投 | | | 20%稅率代扣代繳個人所得稅。 | | 資本公司H股股票 | | | | | 發行人所發行上市權證/可轉換債券的相關信息 | | | | | 發行人所發行上市權證/可轉換債券 不適用 | | | | | 其他信息 | | | | | 其他信息 不適用 | | | | | ...